Fiche personne
Territoire
Franche-Comté
Statut
Hospitalier
Projets
Etude des paramètres immunologiques prédictifs de la rémission moléculaire complète chez les patients atteints de leucémies myéloïde chronique en phase chronique et traités par inhibiteurs de tyrosine kinase (iTKs) (PAMIR-01)
2017 - Porteur du projet : Dr LAROSA Fabrice
Publications
Psychomotor disadaptation syndrome: a scoping review.
Merendino A, Mourey F, Renoncourt T, Da Silva S, Dipanda M, Larosa F, Putot A, Manckoundia P
Eur Geriatr Med. 2025 03 13;:
Fall reveals a liver cyst infection in an older individual.
Manckoundia P, Renoncourt T, Larosa F
Am J Med. 2025 01 30;:
Deciphering Unexpected Vascular Locations of Scedosporium spp. and Lomentospora prolificans Fungal Infections, France.
Vignals C, Emmerich J, Begueret H, Garcia-Hermoso D, Martin-Blondel G, Angoulvant A, Blez D, Bruneval P, Cassaing S, Catherinot E, Cahen P, Moluçon-Chabrot C, Chevenet C, Delhaes L, Escaut L, Faruch M, Grenouillet F, Larosa F, Limousin L, Longchampt E, Mellot F, Nourrisson C, Bougnoux ME, Lortholary O, Roux A, Rozenblum L, Puges M, Lanternier F, Bronnimann D
Emerg Infect Dis. 2024 06;30(6):1077-1087
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE
Leuk Res. 2023 05 9;130:107308
[Inappropriate admissions of Ehpad residents to emergency departments].
Manckoundia P, Ray P, Quipourt V, Vaillard L, Dipanda M, Larosa F, Menu D, Guepet HS, Putot A, Barben J
Soins Gerontol. 2022 12 16;28(159):42-45
Prescription of Blood Lymphocyte Immunophenotyping in the Diagnosis of Lymphoid Neoplasms in Older Adults.
Vovelle J, Row C, Larosa F, Guy J, Mihai AM, Maynadié M, Barben J, Manckoundia P
J Clin Med. 2022 Mar 21;11(6):
Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?
Roggy A, Biichle S, Ferrand C, Renosi F, Larosa F, Deconinck E, Daguindeau E, Collonge Rame MA, Schillinger F, Seilles E, Garnache-Ottou F
Hemasphere. 2021 Aug;5(8):e608
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S,
Leuk Lymphoma. 2021 Feb 17;:1-7
Should We Prescribe Antibiotics in Older Patients Presenting COVID-19 Pneumonia?
Odille G, Girard N, Sanchez S, Lelarge S, Mignot A, Putot S, Larosa F, Vovelle J, Nuss V, Da Silva S, Barben J, Manckoundia P, Putot A
J Am Med Dir Assoc. 2020 Dec 4;:
Positive quantitative PCR detecting Fusarium solani in a case of mixed invasive fungal disease due to Mucorales and Fusarium solani.
Bellanger AP, Rocchi S, Berceanu A, Scherer E, Larosa F, Millon L
Bone Marrow Transplant.. 2020 Feb 5;:
Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor.
Deteix C, Mesnil F, Furst S, Milpied N, Yakoub-Agha I, Fegueux N, Latour RP, Mohty M, Chevallier P, Labussière Wallet H, Huynh A, Larosa F, Bourhis JH, Cahn JY, Chantepie S, Bay JO, Audat F, Foote A, Faucher C, Marry E, Garban F,
Bone Marrow Transplant.. 2019 Oct 29;:
Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients.
Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Réa D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX
Clin. Cancer Res.. 2019 Jul 10;:
Altered thymic CD4 T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis.
Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Saas P, Ferrand C, Seilles E, Pouthier F, Deconinck E, Larosa F
Curr Res Transl Med. 2019 Jun 1;:
CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells.
Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotévi O, Deschamps M, Ferrand C
Cancer Res.. 2018 Dec 4;:
Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study.
Alsuliman T, Kitel C, Dulery R, Guillaume T, Larosa F, Cornillon J, Labussière-Wallet H, Médiavilla C, Belaiche S, Delage J, Alain S, Yakoub-Agha I
Bone Marrow Transplant.. 2018 Apr 13;:
Clinical assessment of a spp. polymerase chain reaction (PCR)-based assay for the diagnosis of nocardiosis.
Rouzaud C, Rodriguez-Nava V, Catherinot E, Méchaï F, Bergeron E, Farfour E, Scemla A, Poirée S, Delavaud C, Mathieu D, Durupt S, Larosa F, Lengelé JP, Christophe JL, Suarez F, Lortholary O, Lebeaux D
J. Clin. Microbiol.. 2018 Mar 21;:
SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.
Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C
Oncoimmunology. 2018 ;7(4):e1412030
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.
Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Didier B, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn JY
Eur. J. Haematol.. 2017 Jan;:
Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.
Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M
Gene Ther.. 2016 Aug;23(8-9):664-72
Combining Aspergillus mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients.
Bellanger AP, Millon L, Berceanu A, Grenouillet F, Grenouillet FE, Larosa F, Deconinck E
Med Mycol. 2015 Jul 10. pii: myv051.
The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Bene MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M
Leuk Res. 2015 Apr;39(4):453-61
[Mucositis after allogeneic stem cell transplantation: Risk factors, clinical consequences and prophylaxis].
Bourdelin M, Daguindau E, Larosa F, Legrand F, Nerich V, Deconinck E, Limat S
Pathol. Biol.. 2015 Apr;63(2):106-10
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C
Exp Hematol Oncol. 2015 ;5:7
Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
Bourdelin M, Grenouillet F, Daguindau E, Muret P, Desbrosses Y, Dubut J, Deconinck E, Limat S, Larosa F
Med. Mycol.. 2014 Oct;52(7):728-35
Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: lack of lymphocyte recovery as a major contributing factor.
Mansi L, Daguindau E, Saas P, Pouthier F, Ferrand C, Dormoy A, Patry I, Garnache F, Rohrlich PS, Deconinck E, Larosa F
Pathol Biol (Paris). 2014 Jun;62(3):156-61
Evaluation of invasive aspergillosis risk for immunocompromised patients alternatively hospitalized in hematology intensive care unit and at home.
Rocchi S, Reboux G, Larosa F, Scherer E, Daguindau E, Berceanu A, Deconinck E, Millon L, Bellanger AP
Indoor Air. 2014 Mar 13
Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients.
Millon L, Larosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E, Scherer E, Bellanger AP, Leroy J, Grenouillet F
Clin Infect Dis. 2013 May;56(10):e95-101
A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.
Martino S, Daguindau E, Ferrand C, Bamoulid J, Hayette S, Nicolini FE, Capellier G, Deconinck E, Larosa F
Leuk Res Rep. 2013 Mar 19;2(1):29-31
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A, Legrand F, Larosa F, Schillinger F, Garnache-Ottou F, Helias P, Fontan J, Heczko M, Delaby P, Daguindau E, Vuillier J, Chauchet A, Deconinck E
Invest New Drugs. 2012 Aug;30(4):1697-702
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.
Lioure B, Bene MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carre M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY
Blood. 2012 Mar 22;119(12):2943-8
Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation.
Ferrand C, Garnache-Ottou F, Collonge-Rame MA, Larosa F, Blanc M, Behar C, Giannoli C, Garnier F, Tiberghien P, Deconinck E, Rohrlich PS
Eur J Haematol. 2012 Mar;88(3):269-72
CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F
Cytometry A. 2012 Jan;81(1):17-24
Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation.
Larosa F, Deconinck E, Helias P, Fontan J, Heczko M, Brion A, Ledu K, Delaby P, Vuiller J, Ferrand C, Saas P, Pouthier F, Dormoy A, Chabod J, Malugani C, Rohrlich PS, Legrand F
Blood. 2011 Jul 14;118(2):476-8.
Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study.
Legrand F, Grenouillet F, Larosa F, Dalle F, Saas P, Millon L, Deconinck E, Rohrlich PS
Bone Marrow Transplant. 2011 Jun;46(6):858-62
Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome.
Larosa F, Maddens S, Legrand F, Pouthier F, Ferrand C, Saas P, Hayette S, Chabod J, Tiberghien P, Rohrlich PS, Deconinck E
Bone Marrow Transplant. 2011 Apr;46(4):622-4
A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhedin N, Delannoy A, Lafage-Pochitaloff M, Bene MC, Ifrah N, Dombret H
Haematologica. 2011 Feb;96(2):245-52
Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors.
Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D, Louvat P, Puyraveau M, Raus N, Tavernier M, Mathieu-Nafissi S, Hequet O, Pouthier F, Deconinck E, Tiberghien P, Robinet E
Transfusion. 2010 Dec;50(12):2676-85
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhedin N
Haematologica. 2010 Jun;95(6):950-5
False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease.
Millon L, Grenouillet F, Crouzet J, Larosa F, Loewert S, Bellanger AP, Deconinck E, Legrand F
Med Mycol. 2010 Jun;48(4):661-4.
G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division.
Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D, Louvat P, Puyraveau M, Raus N, Tavernier M, Mathieu-Nafissi S, Hequet O, Pallandre JR, Vitte F, Collonge-Rame MA, Pouthier F, Bresson JL, Deconinck E, Tiberghien P, Robinet E
Blood. 2010 Jan;115(4):910-1
Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, Francois S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N
Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85
Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen.
Royer B, Larosa F, Legrand F, Gerritsen-van Schieveen P, Berard M, Kantelip JP, Deconinck E
Biol Blood Marrow Transplant. 2009 Sep;15(9):1134-9
A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.
Chevallier P, Hunault-Berger M, Larosa F, Dauriac C, Garand R, Harousseau JL
Leuk Res. 2009 Aug;33(8):1124-6
Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.
Piton G, Larosa F, Minello A, Becker MC, Mantion G, Aubin F, Deconinck E, Hillon P, Di Martino V
Liver Transpl. 2009 Jul;15(7):682-5.
Scedosporium prolificans: an emerging pathogen in France?
Grenouillet F, Botterel F, Crouzet J, Larosa F, Hicheri Y, Forel JM, Helias P, Ranque S, Delhaes L
Med Mycol. 2009 Jun;47(4):343-50
Bone scintigraphy pattern of joint chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Zsigmond R, Ungureanu C, Blagosklonov O, Biancheri I, Angoue O, Runge M, Wendling D, Larosa F, Paycha F, Boulahdour H
Clin Nucl Med. 2009 Jan;34(1):20-3.
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E, Kantelip JP, Marquet P
Clin Pharmacokinet. 2009;48(10):667-75
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM
Haematologica. 2006 Aug;91(8):1027-32.
Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.
Larosa F, Marmier C, Robinet E, Ferrand C, Saas P, Deconinck E, Bulabois CE, Rohrlich PS, Ledu K, Helias P, Tiberghien P, Cahn JY
Bone Marrow Transplant. 2005 May;35(9):859-68.
